Archives

by in
Entry Author Date Location
East Coast Biotech Roundup: Neurophage, Boston Biotech, Insmed, & More 03/28/14 Boston
What’s Hot in Boston Biotech: Here’s the Agenda for April 16 03/27/14 Boston
East Coast Biotech Roundup: Dicerna, J&J, Neurophage, & More 01/31/14 Boston
Dicerna Prices Upsized IPO at $15 Per Share, Starts Trading Thursday 01/29/14 Boston
East Coast Biotech Roundup: JP Morgan Edition 01/17/14 Boston
East Coast Biotech Roundup: Scholar Rock, Dicerna, Eleven, & More 01/03/14 Boston
Dicerna Joins Biotech IPO Queue, Plans $69M Raise 01/02/14 Boston
Arrowhead Picks Up Where Roche Left Off, Jumps Ahead in RNAi 12/20/13 Wisconsin
What Was Hyped, and What Fell Out of Favor, This Year in Biotech 12/16/13 National
San Diego Life Sciences Roundup: Illumina, Mirati, Auspex, and More 10/25/13 San Diego
San Diego’s Arcturus Raises $5M for “Best-in-Class” RNAi Technology 10/22/13 San Diego
Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian 06/10/13 National
Ensysce’s Bet: Combining Two Risky Drug Technologies That Add Up 05/09/13 Texas
AstraZeneca Shells Out $240M Upfront For Moderna mRNA Drugs 03/21/13 Boston
Some Bold Baseball and Biotech Picks for the 2013 Season 03/11/13 National
Shedding Baggage, Alnylam Turns a Corner 02/21/13 Boston
RNA Therapeutics Are Coming of Age 02/08/13 San Diego
Alnylam Gets $25M From Medicines Co. for Cholesterol Drug 02/04/13 Boston
The Fiscal Cliff Is Forcing a Biomedical Day of Reckoning 12/31/12 National
Isis Pharmaceuticals Adds More Deals to Partnership Portfolio 12/12/12 San Diego
Alnylam, Tekmira Look Ahead After RNAi Divorce 11/14/12 Boston
Alnylam to Pay Tekmira $65M to Settle RNAi Delivery Dispute 11/12/12 Boston
Sarepta Drug Helps Boys With Duchenne to Walk; Shares Boom 10/03/12 Boston
Alnylam Inks $29M Deal With Monsanto for New Bio Tools for Farmers 08/28/12 Boston
Brace Yourself: Biotech IPOs Are Beating Tech’s Big Names 08/13/12 National
Sarepta Holds Its Breath as Feds Order Halt to Ebola Work 08/07/12 Seattle
Alnylam Stock Climbs on Positive Early Trial for Amyloidosis 07/16/12 Boston
Marina Biotech Runs Out of Cash, Axes 90% of Staff 06/01/12 Seattle
BioPharma Needs A Safe, Reliable Way To Repair Broken Genes 04/11/12 Seattle
Alnylam Cuts One-Third of Workforce, To Save Cash for RNAi Clinical Plans 01/19/12 Boston
Page 1 of 7 next page »